IHC/IF
(IHC/IF Validation in COVID-19 Patient Sample (Nuovo et al., 2020) Detection of SARS-CoV-2 proteins in nasopharyngeal swab cell preparations F-H. Co-expression of spike detected by spike antibodies (MBS150780) and envelope prot)
Rabbit COVID 19 Envelope Coronavirus Polyclonal Antibody | anti-COVID-19 antibody
SARS-CoV-2 (COVID-19) Envelope antibody (biotin)
Predicted reactivity based on immunogen sequence: SARS-CoV Envelope proteins: (100%)
Predicted reactivity based on immunogen sequence: SARS-CoV Envelope proteins: (100%)
The immunogen is located within the first 50 amino acids of SARS-CoV-2 (COVID-19, 2019-nCoV) Envelope.
IHC/IF
(IHC/IF Validation in COVID-19 Patient Sample (Nuovo et al., 2020) Detection of SARS-CoV-2 proteins in nasopharyngeal swab cell preparations F-H. Co-expression of spike detected by spike antibodies (MBS150780) and envelope prot)
IHC/IF
(IHC/IF Validation in COVID-19 Patient Sample (Nuovo et al., 2020) Detection of SARS-CoV-2 proteins in nasopharyngeal swab cell preparations F-H. Co-expression of spike detected by spike antibodies (MBS150780) and envelope prot)
IHC/IF
(Validation in COVID-19 Patient Sample (Nuovo et al., 2020) Detection of SARS-CoV-2 proteins in nasopharyngeal swab cell preparations F-H. Co-expression of spike detected by spike antibodies (MBS150780) and envelope proteins detected by envelope antibodies (MBS150849) of SARSCoV-2 (panel F) documented localization of each protein to glandular cells with negative squamous cells two weeks after full recovery (panel G, signal yellow). No signal was seen in oral swabs of positive cases (panel H). Both the spike and envelope protein detected by anti-spike antibodies (MBS150780, 0.2 ug/mL) and anti-envelope antibodies (MBS150849, 2 ug/mL) produced a signal in the nasopharyngeal swabs of the three cases and no signal was evident in the nasopharyngeal swabs of the seven controls.)
IHC/IF
(Validation in COVID-19 Patient Sample (Nuovo et al., 2020) Detection of SARS-CoV-2 proteins in nasopharyngeal swab cell preparations F-H. Co-expression of spike detected by spike antibodies (MBS150780) and envelope proteins detected by envelope antibodies (MBS150849) of SARSCoV-2 (panel F) documented localization of each protein to glandular cells with negative squamous cells two weeks after full recovery (panel G, signal yellow). No signal was seen in oral swabs of positive cases (panel H). Both the spike and envelope protein detected by anti-spike antibodies (MBS150780, 0.2 ug/mL) and anti-envelope antibodies (MBS150849, 2 ug/mL) produced a signal in the nasopharyngeal swabs of the three cases and no signal was evident in the nasopharyngeal swabs of the seven controls.)
Immunohistochemistry (IHC)
(IHC Validation in COVID-19 Patient Sample (Nuovo et al., 2020) Detection of SARS-CoV-2 Envelope protein in nasopharyngeal swab samples of COVID-19 patients Panel F shows Envelope protein detected by envelope antibodies (MBS150849, 2 ug/mL) was still evident 2 weeks after the initial swabs (signal is red with hematoxylin counterstain), though the amount of virus was much less than at the initial swab.)
Immunohistochemistry (IHC)
(IHC Validation in COVID-19 Patient Sample (Nuovo et al., 2020) Detection of SARS-CoV-2 Envelope protein in nasopharyngeal swab samples of COVID-19 patients Panel F shows Envelope protein detected by envelope antibodies (MBS150849, 2 ug/mL) was still evident 2 weeks after the initial swabs (signal is red with hematoxylin counterstain), though the amount of virus was much less than at the initial swab.)
Immunohistochemistry (IHC)
(IHC Validation of Envelope in COVID-19 Patient Skin (Magro et al., 2020) Detection of SARS-CoV-2 Envelope protein in the blood vessels of COVID-19 patients that were confirmed by PCR. The staining shows Envelope protein expression (green) detected by envelope antibodies (MBS150849, 3 ug/mL) in the endothelial cytoplasms in thrombosed and normal appearing blood vessels with hematoxylin counterstain. The staining was negative in control normal skin/lung (not shown).)
Immunohistochemistry (IHC)
(IHC Validation of Envelope in COVID-19 Patient Skin (Magro et al., 2020) Detection of SARS-CoV-2 Envelope protein in the blood vessels of COVID-19 patients that were confirmed by PCR. The staining shows Envelope protein expression (green) detected by envelope antibodies (MBS150849, 3 ug/mL) in the endothelial cytoplasms in thrombosed and normal appearing blood vessels with hematoxylin counterstain. The staining was negative in control normal skin/lung (not shown).)
Immunofluorescence (IF)
(IF Validation of Envelope in COVID-19 Patient Skin (Magro et al., 2020) Detection of SARS-CoV-2 Envelope protein in the skin of COVID-19 patients that were confirmed by PCR. The skin staining shows Envelope protein expression (green) detected by envelope antibodies (MBS150849, 3 ug/mL) in mononuclear cells with hematoxylin counterstain. The staining was negative in control normal skin/lung (not shown).)
Immunofluorescence (IF)
(IF Validation of Envelope in COVID-19 Patient Skin (Magro et al., 2020) Detection of SARS-CoV-2 Envelope protein in the skin of COVID-19 patients that were confirmed by PCR. The skin staining shows Envelope protein expression (green) detected by envelope antibodies (MBS150849, 3 ug/mL) in mononuclear cells with hematoxylin counterstain. The staining was negative in control normal skin/lung (not shown).)
Immunofluorescence (IF)
(Immunofluorescence Validation of SARSCoV-2 (COVID-19) Envelope in Human Lung Tissue from the COVID-19 Patient Immunofluoorescent l analysis of paraffin-embedded COVID-19 patient lung tissue using anti- SARS-CoV-2 (COVID-19) Envelope antibody (MBS150849, 2 ug/mL). Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4°C, followed by a goat anti-rabbit IgG secondary antibody at 1/500 (red) and DAPI staining (blue). (Courtesy of Dr. Nuovo Gerard J., OSU) .)
Immunofluorescence (IF)
(Immunofluorescence Validation of SARSCoV-2 (COVID-19) Envelope in Human Lung Tissue from the COVID-19 Patient Immunofluoorescent l analysis of paraffin-embedded COVID-19 patient lung tissue using anti- SARS-CoV-2 (COVID-19) Envelope antibody (MBS150849, 2 ug/mL). Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4°C, followed by a goat anti-rabbit IgG secondary antibody at 1/500 (red) and DAPI staining (blue). (Courtesy of Dr. Nuovo Gerard J., OSU) .)
Immunofluorescence (IF)
(Co-expression of SARS-CoV-2 (COVID-19) Envelope and C5b-9 in Human Lung Tissue from the COVID-19 Patient Immunofluorescent l analysis of paraffin-embedded COVID-19 patient lung tissue using anti- SARS-CoV-2 (COVID-19) Envelope antibody (MBS150849, 2 ug/mL, red) and anti-C5b-9 antibody (green). Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4°C, followed by secondary antibodies at 1/500 and DAPI staining (blue). Coexpression was shown in yellow. (Courtesy of Dr. Nuovo Gerard J., OSU).)
Immunofluorescence (IF)
(Co-expression of SARS-CoV-2 (COVID-19) Envelope and C5b-9 in Human Lung Tissue from the COVID-19 Patient Immunofluorescent l analysis of paraffin-embedded COVID-19 patient lung tissue using anti- SARS-CoV-2 (COVID-19) Envelope antibody (MBS150849, 2 ug/mL, red) and anti-C5b-9 antibody (green). Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4°C, followed by secondary antibodies at 1/500 and DAPI staining (blue). Coexpression was shown in yellow. (Courtesy of Dr. Nuovo Gerard J., OSU).)
ELISA (EIA)
(ELISA Test Antibodies: SARS-CoV-2 (COVID-19, 2019-nCoV) Envelope Antibody, 3531 (1 ug/mL). A direct ELISA was performed using antigen or control peptide as coating antigen and the anti-SARS-CoV-2 (COVID-19, 2019-nCoV) Envelope antibody as the capture antibody. Secondary: Goat antirabbit IgG HRP conjugate at 1:20000 dilution. Detection range is from 32 ng/mL to 2000ng/mL.)
ELISA (EIA)
(ELISA Test Antibodies: SARS-CoV-2 (COVID-19, 2019-nCoV) Envelope Antibody, 3531 (1 ug/mL). A direct ELISA was performed using antigen or control peptide as coating antigen and the anti-SARS-CoV-2 (COVID-19, 2019-nCoV) Envelope antibody as the capture antibody. Secondary: Goat antirabbit IgG HRP conjugate at 1:20000 dilution. Detection range is from 32 ng/mL to 2000ng/mL.)
Hui et al. Int J Infect Dis. 2020;91:264-266.
Pervushin et al. PLoS Pathog. 2009; 5(7): e1000511.
Nuovo GJ et al. Cytologic and molecular correlates of SARS-CoV-2 infection of the nasopharynx. Ann Diagn Pathol. 2020; 48:151565. doi: 10.1016/j.anndiagpath.2020.151565. PMID: 32659620
Magro C, Mulvey JJ, Laurence J, Sanders S, Crowson N, Grossman M, Harp J, Nuovo G. The differing pathophysiologies that underlie COVID-19 associated perniosis and thrombotic retiform purpura: a case series. Br J Dermatol. 2020; 22:10.1111/bjd.19415. doi: 10.1111/bjd.19415. PMID: 32779733
Nuovo G, Tili E, Suster D, Matys E, Hupp L, Magro C. Strong homology between SARS-CoV-2 envelope protein and a Mycobacterium sp. antigen allows rapid diagnosis of Mycobacterial infections and may provide specific anti-SARS-CoV-2 immunity via the BCG vaccine. Ann Diagn Pathol. 2020; 48:151600. doi: 10.1016/j.anndiagpath.2020.151600. PMID: 32805515
Ko, et al. Discordant anti-SARS-CoV-2 spike protein and RNA staining in cutaneous perniotic lesions suggests endothelial deposition of cleaved spike protein. J Cutan Pathol. 2021 Jan;48(1):47-52. doi: 10.1111/cup.13866. Epub 2020 Oct 1.PMID: 32895985
Magro, et al. Docked severe acute respiratory syndrome coronavirus 2 proteins within the cutaneous and subcutaneous microvasculature and their role in the pathogenesis of severe coronavirus disease 2019. Hum Pathol. 2020 Dec;106:106-116. doi: 10.1016/j.humpath.2020.10.002. Epub 2020 Oct 12.PMID: 33058948
Magro, et al. The differing pathophysiologies that underlie COVID-19-associated perniosis and thrombotic retiform purpura: a case series. Br J Dermatol. 2020 Jul 22;10.1111/bjd.19415. doi: 10.1111/bjd.19415PMID: 32779733
Mulvey, et al. Analysis of complement deposition and viral RNA in placentas of COVID-19 patients. Ann Diagn Pathol. 2020 Jun;46:151530. doi: 10.1016/j.anndiagpath.2020.151530. Epub 2020 Apr 25.PMID: 32387855
Rotman, et al. Concomitant calciphylaxis and COVID-19 associated thrombotic retiform purpura. Skeletal Radiol. 2020 Nov;49(11):1879-1884. doi: 10.1007/s00256-020-03579-6. Epub 2020 Aug 26.PMID: 32844243
NCBI and Uniprot Product Information
Similar Products
Product Notes
The COVID-19 (Catalog #AAA154772) is an Antibody produced from Rabbit and is intended for research purposes only. The product is available for immediate purchase. The SARS-CoV-2 (COVID-19) Envelope antibody (biotin) reacts with Virus Predicted reactivity based on immunogen sequence: SARS-CoV Envelope proteins: (100%) and may cross-react with other species as described in the data sheet. It is sometimes possible for the material contained within the vial of "COVID 19 Envelope Coronavirus, Polyclonal Antibody" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
